ATM

Central bank digital currency and monetary policy implementation

Retrieved on: 
목요일, 4월 18, 2024
E41, Central bank digital currency, Atlantic Council, Research Papers in Economics, Remuneration, Norges Bank, People's Bank of China, Policy, Central Bank of Myanmar, Bank for International Settlements, Blog, Financial innovation, Sveriges Riksbank, Bank of Canada, Mechanics, Journal of Monetary Economics, Insurance, Bank of England, E42, Corridor, Quarterly Journal of Economics, Report card, Frankfurt, Appetite, American Economic Association, Digital rupee, Rosolin, RBI, PDF, Private, ECB, Committee, Inden, North Rhine-Westphalia, Bank, Canadian International Council, Social science, JEL, JMD, ECCB, Digital, Journal, Research, POC, European Central Bank, ENaira, M.A, Monetary economics, Section 5, Government, ISSN, The, Central bank, Finance, Buffer, Parliament, CBN, EONIA, Asset, ATM, Risk, International Monetary Fund, Interbank, Section 4, Ministry, Press release, Section 3, Human, Waterfall, Cryptocurrency, Economy, Swiss National Bank, PIB, Section 2, Conference, Reserve Bank, Reserve Bank of India, GBP, Progress, Road, American Economic Review, CBB, Digital currency, Agur, European Commission, International Settlement, Constraint, Money, Community business development corporation, City, Equivalence, Eligibility, Ministry of Finance, Report, Control, Civil service commission, EUR, Uncertainty, Eastern Caribbean Central Bank, Abadi, Rest, Reproduction, Fintech, IMF, Federal Reserve, LCR, Data
Key Points: 

    Transactional demand for central bank digital currency

    Retrieved on: 
    목요일, 4월 18, 2024
    POS, Learning, CB, E41, Calibration, Financial regulation, Interest, ATM, Oesterreichische Nationalbank, Journal of Macroeconomics, Sensitivity, Diffusion, ITunes, Bank of Canada, P2P, Safety, NBER, Benchmarking, Prevalence, SPACE, Bernoulli, Journal of Monetary Economics, E42, Paper, European Parliamentary Research Service, Apollo, Environment, Political economy, COVID-19, Review of Economic Dynamics, Abramov, Loss, Working paper, Choice, Collection, Probability, Dowd, Castrén, Face, Noise, History, Restaurant, Journal of Political Economy, ECB, Policy, Diary, Model, Utility, Clutch (eggs), Canadian International Council, Journal of Financial Stability, JEL, Digital, Bias, Journal, Research, Classification, CBDC, SARS-CoV-2, ECMI, Credit, Odds ratio, Literature, European Central Bank, Mises Institute, Monetary economics, Section 5, Occupation, E47, Financial intermediary, Government, Supermarket, Friction, Finance, BIS, Love, Bart, The Economic Journal, Education, Risk, Section 4, Privacy, Section 3, Appetite, App Store (iOS/iPadOS), Human, DNB, International finance, Section 2, Leonhard Euler, Payment, Attention, Central bank, Consumer, EPRS, Habit, American Economic Review, Confidence interval, FCO, Central bank digital currency, Exercise, Letizia, Applied economics, Digital currency, Sale, Business cycle, Amazon, Community business development corporation, Control, Chart, Proxy, American Economic Journal, LN, Bank, Fintech, IMF, Analysis, Aggregation, Cryptocurrency
    Key Points: 

      Ivy Brain Tumor Center Announces Promising Results of Phase 0/1 Glioblastoma Study at the American Association for Cancer Research Annual Meeting

      Retrieved on: 
      금요일, 4월 5, 2024
      Radiation, Brain, Patient, DNA, Ben, Hope, MD, AACR, Glioblastoma, ATM, Barrow Neurological Institute, Hedera, Medical imaging

      Results from this study will be presented at the American Association for Cancer Research Annual Meeting and demonstrate that AZD1390 may be a potent radiosensitizer in both newly diagnosed and recurrent glioblastoma patients.

      Key Points: 
      • Results from this study will be presented at the American Association for Cancer Research Annual Meeting and demonstrate that AZD1390 may be a potent radiosensitizer in both newly diagnosed and recurrent glioblastoma patients.
      • Study results show AZD1390 is well tolerated in this patient population, that the drug achieved high concentrations in patients’ tumor tissue and successfully modulates its target in this tissue.
      • Ivy Brain Tumor Center scientists and investigators will also present seven posters highlighting results from preclinical and clinical studies at the meeting.
      • This is an investigator-initiated study funded by the Ben & Catherine Ivy Foundation and Barrow Neurological Foundation.

      Operational Security Solutions (OSS) Further Digitizes its Cash Logistics Offering with Morphis, Inc.; Adding SmartSafe and ATM Solutions

      Retrieved on: 
      목요일, 4월 4, 2024
      Organization, Forecasting, Partnership, OSS, Operational definition, ATM, Movement, Cryptocurrency

      Following the announcement of its web portal offering, OSS has now worked with Morphis to integrate the digital platform into all aspects of its cash logistics services including its SmartSafe program, provisional crediting system (where available), and ATM servicing.

      Key Points: 
      • Following the announcement of its web portal offering, OSS has now worked with Morphis to integrate the digital platform into all aspects of its cash logistics services including its SmartSafe program, provisional crediting system (where available), and ATM servicing.
      • All through one simple to use dashboard, customers of OSS are given full transparency into their cash logistics.
      • “In our mission to exceed customer expectations, embracing digital transformation was not only inevitable but crucial,” said Scott Solomon, Chief Executive Officer of Operational Security Solutions.
      • OSS has partnered with a leading SmartSafe supplier and is now offering full SmartSafe integration solutions including equipment procurement, installation and training to businesses and financial institution partners nationwide.

      Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results

      Retrieved on: 
      화요일, 4월 2, 2024
      Research, Failure, Plasma, KPMG, TDP43, Disease, PD, CSF, Yale University, Patient, Inflammation, Biomarker, CMC, Equity, TAR, Human, European, Drug development, ATM, Safety, Phase, Therapy, Vaccine, Treasury, Syneos Health, Axonal transport, Pharmaceutical industry

      MALVERN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today provided a summary of corporate updates and reported fourth quarter and full year 2023 financial results.

      Key Points: 
      • MALVERN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today provided a summary of corporate updates and reported fourth quarter and full year 2023 financial results.
      • For the quarter ended December 31, 2023, Annovis reported a net loss of $22.2 million, compared to a net loss of $7.7 million for the same period in 2022.
      • For the full year ended 2023, Annovis reported a net loss of $56.2 million, compared to a net loss of $25.3 million in 2022.
      • Other income (expense) for the quarter ended December 31, 2023 was ($11.2) million, compared to $0.2 million for the same period in 2022.

      Clever Leaves Reports Fourth Quarter and Full Year 2023 Results

      Retrieved on: 
      월요일, 4월 1, 2024
      Financial statement, Certification, HBI, Consolidated, Partnership, Accounting Standards Codification, Patient, Sale, RDC, Sales, Closing, GMP, Procurement, ASC, Traction, Interest, ATM, Security, Note, Investment, THC, Pharmaceutical industry

      TOCANCIPÁ, Colombia, April 01, 2024 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) (“Clever Leaves” or the “Company”), a global medicinal cannabis company, is reporting financial and operating results for the fourth quarter and full year ended December 31, 2023. All financial information is provided in US dollars unless otherwise indicated.

      Key Points: 
      • Subsequent to the end of the fourth quarter, we completed the $1.5 million sale of our Portuguese farm assets.
      • As we progress into 2024, we remain focused on driving further capital preservation and operational efficiencies.”
        Fourth Quarter 2023 Summary vs.
      • Same Year-Ago Quarter1
        Revenue in the fourth quarter of 2023 increased 5% to $4.6 million compared to $4.4 million for the same period in 2022.
      • Net loss in 2023 includes a $3.7 million loss on investment related to the fourth quarter sale of the Company’s remaining Cansativa stake.

      Stryve Foods, Inc. Reports Full Year Fiscal 2023 Results

      Retrieved on: 
      월요일, 4월 1, 2024
      Absorption, Growth, Acceleration, ATM, GAAP, Rationalization, Economics, SKUS

      PLANO, Texas, April 01, 2024 (GLOBE NEWSWIRE) -- Stryve Foods, Inc. (“Stryve” or “the Company”) (NASDAQ: SNAX), an emerging healthy snacking platform and leader in the air-dried meat snack industry in the United States, today reports financial and operating results for the three months and twelve months ended December 31, 2023.

      Key Points: 
      • Chris Boever, Chief Executive Officer, commented, “2023 marked a year of strategic transformation for Stryve, underpinned by our commitment to operational excellence and market expansion.
      • Adjusted EBITDA loss3 of ($3.4) million for the 2023 fourth quarter, compared to ($3.5) million in the prior year quarter.
      • The Company will conduct a conference call today at 4:30 p.m. Eastern Time to discuss financial and operating results for the third quarter ended September 30, 2023.
      • A telephonic replay will be available through November 28, 2023, by calling (844) 512-2921 and using passcode ID:148214195.

      Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023

      Retrieved on: 
      목요일, 3월 28, 2024
      Narcolepsy, Toxicity, Administration, Development, ASH, ABR, Haemophilia, Part, APC, Tumor microenvironment, Observation, Volunteering, Trial of the century, CD47, Investment, Society, Bleeding, CNTA, ATM, Safety, OX2R, Sleep, Person, Pharmaceutical industry

      “This is an exciting and pivotal time for Centessa,” said Saurabh Saha MD PhD, Chief Executive Officer of Centessa.

      Key Points: 
      • “This is an exciting and pivotal time for Centessa,” said Saurabh Saha MD PhD, Chief Executive Officer of Centessa.
      • Cash, Cash Equivalents and Short-term Investments: $256.5 million as of December 31, 2023, which includes approximately $6.2 million in net proceeds through ATM sales in the fourth quarter ended December 31, 2023.
      • General & Administrative Expenses: $12.3 million for the fourth quarter ended December 31, 2023, compared to $13.8 million the fourth quarter ended December 31, 2022, and $53.7 million for the full-year 2023 compared to $55.2 million for the full-year 2022.
      • Net Loss Attributable to Ordinary Shareholders: $36.8 million for the fourth quarter ended December 31, 2023, compared to $43.2 million for the fourth quarter ended December 31, 2022, and $151.1 million for the full-year 2023 compared to $216.2 million for the full-year 2022.

      Wintrust Wins Highest Ranking by J.D. Power for Illinois Retail Banking Customer Satisfaction for the Third Year in a Row

      Retrieved on: 
      목요일, 3월 28, 2024
      ATM, J.D. Power, Small business, Community Bank

      ROSEMONT, Ill., March 28, 2024 (GLOBE NEWSWIRE) -- Wintrust Financial Corporation (Nasdaq:WTFC) today announced that Wintrust Community Banks received the award for ranking highest in the J.D.

      Key Points: 
      • ROSEMONT, Ill., March 28, 2024 (GLOBE NEWSWIRE) -- Wintrust Financial Corporation (Nasdaq:WTFC) today announced that Wintrust Community Banks received the award for ranking highest in the J.D.
      • Power 2024 U.S. Retail Banking Satisfaction Study in the Illinois Region for the third consecutive year.
      • Power study is based on rating responses from 105,355 retail banking customers in seven dimensions.
      • This year’s honor continues Wintrust’s ranking as the highest in Illinois in both 2022 and 2023.

      Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results

      Retrieved on: 
      목요일, 3월 28, 2024
      Research, HCPCS, Gait, Patient, Operating cost, Stroke, Sale, Acquisition, HSDT, Andreyev, Social services, ATM, Pons, Medicare, FDA, CMS, PTAP, Food, Video game

      NEWTOWN, Pa., March 28, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced results for the quarter and full year ended December 31, 2023.

      Key Points: 
      • Gross profit for the fourth quarter of 2023 was $44 thousand, compared to gross profit of $132 thousand in the fourth quarter of 2022.
      • Operating loss for the fourth quarter of 2023 decreased to a loss of $2.2 million, compared to an operating loss of $2.7 million in the fourth quarter of 2022.
      • Net loss was $1.0 million for the fourth quarter of 2023, compared to a net loss of $4.9 million in the fourth quarter of 2022.
      • The basic and diluted net loss per share for the fourth quarter 2023 was $1.47, compared to net loss per share of $8.66 in the fourth quarter 2022.